Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

  • Alessandra Fabi1Email author,
  • Michelangelo Russillo1,
  • Gianluigi Ferretti1,
  • Giulio Metro1,
  • Cecilia Nisticò1,
  • Paola Papaldo1,
  • Ferdinando De Vita2,
  • Giuliana D’Auria3,
  • Antonello Vidiri4,
  • Diana Giannarelli5 and
  • Francesco Cognetti1
BMC Cancer201212:482

DOI: 10.1186/1471-2407-12-482

Received: 27 December 2011

Accepted: 22 September 2012

Published: 19 October 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
27 Dec 2011 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
12 Jan 2012 Reviewed Reviewer Report - Antonio Frassoldati
11 Mar 2012 Reviewed Reviewer Report - Sara Hurvitz
11 Apr 2012 Author responded Author comments - Alessandra Fabi
Resubmission - Version 3
11 Apr 2012 Submitted Manuscript version 3
2 Jul 2012 Reviewed Reviewer Report - Antonio Frassoldati
3 Jul 2012 Reviewed Reviewer Report - Sara Hurvitz
6 Aug 2012 Author responded Author comments - Alessandra Fabi
Resubmission - Version 4
6 Aug 2012 Submitted Manuscript version 4
2 Sep 2012 Reviewed Reviewer Report - Sara Hurvitz
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
22 Sep 2012 Editorially accepted
19 Oct 2012 Article published 10.1186/1471-2407-12-482

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Division of Medical Oncology A, Regina Elena National Cancer Institute
(2)
Division of Medical Oncology, Second University of Naples School of Medicine, II Policlinico
(3)
Division of Medical Oncology, Belcolle Hospital
(4)
Diagnostic Imaging Department, Regina Elena National Cancer Institute
(5)
Service of Biostatistics, Regina Elena National Cancer Institute

Advertisement